EANS-Voting Rights

Marinomed Biotech AG / Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act - Seite 2

| | | |Number of voting | |
| | | | rights that may | |
|Type of |Expiration Date| Exercise Period| be acquired if |% of voting|
|instrument| | |the instrument is|rights |
|__________|_______________|_________________|____exercised____|___________|
|__________|_______________|_________________|_________________|___________|
|__________________________|_____SUBTOTAL_B.1|_________________|___________|

________________________________________________________________________
|B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 |
|BörseG_2018_____________________________________________________________|
| |Expiration|Exercise|Physical / Cash|Number of |% of voting|
|Type of |Date |Period |Settlement |voting rights|rights |
|instrument|__________|________|_______________|_____________|___________|
|__________|__________|________|_______________|_____________|___________|
|______________________________|_SUBTOTAL_B.2__|_____________|___________|



8. Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the
financial/other instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

______________________________________________________________________________
| | | | | Financial/ | |
| | | Directly |Shares held | other |Total of both|
| No. | Name | controlled |directly (%)|instruments | (%) |
| | | by No. | | held | |
|____________|____________|____________|____________|directly_(%)|_____________|
|___________1|__Jan_Vedral|____________|______0.00_%|______0.00_%|_______0.00_%|
| | Conseq| | | | |
| 2| Investment| 1| 0.00 %| 0.00 %| 0.00 %|
| | Management,| | | | |
|____________|________a.s.|____________|____________|____________|_____________|
| | Conseq| | | | |
| 3| Penzijní| 2| 0.00 %| 0.00 %| 0.00 %|
| | spole¿nost,| | | | |
|____________|________a.s.|____________|____________|____________|_____________|
| | Conseq| | | | |
| | globální| | | | |
| 4| akciový| 3| 2.33 %| 0.00 %| 2.33 %|
| | úcastnický| | | | |
|____________|________fond|____________|____________|____________|_____________|
| 5| Conseq| | 0.00 %| 0.00 %| 0.00 %|
|____________|__Invest_Plc|____________|____________|____________|_____________|
| | Conseq| | | | |
| 6|Invest Akcie| 5| 1.75 %| 0.00 %| 1.75 %|
|____________|_Nové_Evropy|____________|____________|____________|_____________|


9. In case of proxy voting
Date of general meeting: -
Voting rights after general meeting: - is equivalent to - voting rights.

10. Other comments:
Shares are held by two investment funds managed by investment companies as
stated above acting in concert.



Further inquiry note:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T [phone]
E-Mail: [e-mail]
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T [phone]
E-Mail: [e-mail]
http://www.metrum.at


end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: [phone]
FAX: [phone]
mail: [e-mail]
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Additional content: https://www.presseportal.de/pm/132651/4532718
OTS: Marinomed Biotech AG